Home › Research › Biomarkers
Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience
Federica Agosta, Giordano Cecchetti, Edoardo G Spinelli, Alma Ghirelli, Giulia Rugarli, Stefano Pisano, Federico Coraglia, Elisa Canu et al.. Alzheimer's research & therapy, 2026-03-20
Topic: Drug trials: efficacy and safety
Plain-language summary
ARIA were infrequent. In donanemab-treated patients, mildly symptomatic ARIA-E occurred in 10% (2/20) and asymptomatic ARIA-H in 15% (3/20). In lecanemab-treated patients, asymptomatic ARIA-H occurred in 11% (1/9). Infusion-related reactions occurred in 21% (6/29) of treatment courses and were manageable with standardized premedication. Among 11 patients with six-month follow-up, amyloid burden decreased significantly (mean change − 52.4 Centiloids), and 75% of donanemab-treated patients (6/8) and 0% of lecanemab-treated patients reached amyloid positron emission tomography negativity (< 11CL). Plasma phosphorylated tau 181 and glial fibrillary acidic protein showed directional declines, consistent with expected biomarker trajectories under anti-amyloid therapy, while cognitive measures showed no significant change. In a structured multidisciplinary framework, lecanemab and donanemab were feasibly implemented with a preliminary favorable early safety profile, substantial amyloid reduction, and measurable plasma biomarker changes in routine practice. This experience supports the feasibility of structured real-world pathways for deployment and monitoring of disease-modifying therapies in European memory clinics, within the limitations of a small cohort and short follow-up.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Agosta, F., Cecchetti, G., Spinelli, E. G., Ghirelli, A., Rugarli, G., Pisano, S., et al. (2026). Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-026-02015-6
Vancouver
Agosta F, Cecchetti G, Spinelli EG, Ghirelli A, Rugarli G, Pisano S, et al. Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience. Alzheimer's research & therapy. 2026. doi:10.1186/s13195-026-02015-6. PMID: 41857623.
BibTeX
@article{agosta2026-41857623,
author = {Agosta, Federica and Cecchetti, Giordano and Spinelli, Edoardo G and Ghirelli, Alma and Rugarli, Giulia and Pisano, Stefano and Coraglia, Federico and Canu, Elisa and others},
title = {{Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience}},
journal = {Alzheimer's research \& therapy},
year = {2026},
doi = {10.1186/s13195-026-02015-6},
pmid = {41857623},
url = {https://doi.org/10.1186/s13195-026-02015-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In donanemab-treated patients, mildly symptomatic ARIA-E occurred in 10% (2/20) and asymptomatic ARIA-H in 15% (3/20).
- In lecanemab-treated patients, asymptomatic ARIA-H occurred in 11% (1/9).
- Infusion-related reactions occurred in 21% (6/29) of treatment courses and were manageable with standardized premedication.
- Among 11 patients with six-month follow-up, amyloid burden decreased significantly (mean change − 52.4 Centiloids), and 75% of donanemab-treated patients (6/8) and 0% of lecanemab-treated patients reached amyloid positron emission tomography negativity (< 11CL).
- Plasma phosphorylated tau 181 and glial fibrillary acidic protein showed directional declines, consistent with expected biomarker trajectories under anti-amyloid therapy, while cognitive measures showed no significant change.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 66/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 37 of the 56 points we could judge it on, which is 66 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41857623) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 37 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 37 of the 56 points we could judge it on is 66 out of 100. |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.